ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Photobiomodulation to minimize talquetamab-associated dysgeusia and xerostomia in multiple myeloma: a brief report of four cases.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTalquetamab, a GPRC5D-targeting bispecific antibody, produces high response rates in relapsed/refractory multiple myeloma (RRMM) but is frequently associated with oral adverse effects, most commonly dysgeusia and xerostomia, which can impair nutrition and quality of life. No evidence-based supportive-care intervention has been established for these effects.
methodsWe describe four adults with RRMM who received photobiomodulation (PBM) concomitantly with talquetamab, using a dual-wavelength (660/808 nm) protocol individualized to symptom evolution and patient availability. Dysgeusia and xerostomia were assessed prospectively at each session through structured clinical interview and oral examination, with severity graded for each patient; no formal psychophysical gustatory testing or sialometry was performed. This descriptive, uncontrolled case series was designed to report the feasibility and tolerability of PBM rather than its efficacy.
resultsAll four patients developed dysgeusia during talquetamab treatment. Two had grade 1, intermittent hypogeusia; two had grade 2 dysgeusia with complete taste loss (ageusia). No patient developed oral mucositis or clinically significant oral pain. All four patients reported xerostomia, with reduced salivary film and whitish, viscous saliva on examination; salivary flow was not measured quantitatively. All patients also received xylitol-based mouthwash and saliva substitutes from the start of talquetamab as concomitant standard supportive care. PBM was well tolerated, with no PBM-related adverse events, and no patient discontinued talquetamab because of oral toxicity.
conclusionsThis series demonstrates the feasibility and tolerability of PBM delivered alongside talquetamab in four patients. Given the small, uncontrolled sample and concurrent supportive interventions, no conclusion can be drawn regarding the efficacy of PBM for talquetamab-associated dysgeusia or xerostomia. Controlled studies with objective, validated outcome measures are needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.